Compare GE HealthCare Technologies Inc. Common Stock (GEHC) vs Lemonade Inc (LMND) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
GE HealthCare Technologies Inc. Common Stock vs Lemonade Inc — how do they compare? GE HealthCare Technologies Inc. Common Stock trades at $68.66 (market cap $31.07B), while Lemonade Inc trades at $43.49 (market cap $3.46B). The key difference: GE HealthCare Technologies Inc. Common Stock is far larger — about 9× Lemonade Inc's market cap, and GE HealthCare Technologies Inc. Common Stock pays a 0.23% dividend while Lemonade Inc pays none. Which is the better fit depends on your goals.
| GEHC | LMND | |
|---|---|---|
Market Cap | $31.07B | $3.46B |
Volume | 3,443,020 | 1,011,472 |
Sector | Health | Financials |
52-Week High | $88.16 | $96.57 |
52-Week Low | $59.48 | $43.86 |
Enterprise Value | $39.53B | $3.32B |
Dividend Yield | 0.23% | — |
Typical Hold Time | — | 27 Days |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
GE HealthCare (GEHC) trades at $68.79, up 1.55% today, with a neutral technical signal. The company reported mixed quarterly earnings, beating in Q2 2026 but missing in Q1, and is set to announce Q3 results on October 28, 2026. Recent developments include a $945 million acquisition of SOFIE Biosciences to expand its PET radiopharmaceutical footprint, alongside ongoing securities fraud investigations noted in recent news.
The outlook is cautiously optimistic, supported by a strong analyst consensus with a $79.64 price target and no sell ratings. Key opportunities include growth from strategic acquisitions and AI innovations, while risks involve legal investigations, integration challenges from the SOFIE deal, and potential margin pressures from increased investing cash outflows in 2026.
Lemonade (LMND) trades at $43.86, down 2.86% on the day, with technical indicators showing bearish momentum despite recent earnings beats. The company continues to show strong revenue growth, with 2025 revenue reaching $738 million and improving margins, though it remains unprofitable with a net loss of $166 million. Recent expansion into Alaska and Kentucky, along with AI-driven efficiency improvements, supports the company's path toward EBITDA profitability by late 2026.
While Lemonade shows promising growth and margin improvement, the stock faces near-term technical pressure and persistent profitability challenges. The consensus price target of $67 offers significant upside potential, but investors must weigh expansion opportunities against ongoing losses and competitive pressures in the insurtech space.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
No sentiment data available yet.
About GE HealthCare Technologies Inc. Common Stock
GE HealthCare Technologies Inc. is a medical technology company, spun off from General Electric in 2023, that develops imaging systems, ultrasound devices, patient monitoring equipment, and diagnostic imaging agents. Its product lines include CT, MRI, and mammography systems alongside anesthesia delivery and maternal-infant care solutions.
Read more on GEHC →About Lemonade Inc
Lemonade Inc operates in the insurance industry. The company offers digital and artificial intelligence based platform for various insurances and for settling claims and paying premiums. The platform ensures transparency in issuing policies and settling disputes.
Read more on LMND →
